Article Text

Download PDFPDF
Archivist
BANDIT study: preserving β-cell function in recently diagnosed type 1 diabetes

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Janus kinase inhibitors (JAKi) are effective disease-modifying treatments for autoimmune diseases such as juvenile idiopathic arthritis, alopecia and eczema. JAK are cytoplasmic non-receptor tyrosine kinases involved in chronic inflammation. There are four recognised members (JAK1, JAK2, JAK3 and TYK2) and they act by transducing cytokine signalling which in turn regulates several genes involved with inflammation. Tofacitinib, abrocitinib, baricitinib, upadacitinib and filgotinib are the most common JAKi available. Some are administered intravenously but baricitinib is taken orally. Waibel M et al (N Engl J Med 2023;389:2140–2150. DOI: 10.1056/NEJMoa2306691) have completed a phase 2, double-blind, randomised, placebo-controlled trial. In the 91 children …

View Full Text

Footnotes

  • Provenance and peer review Commissioned; internally peer reviewed.